Lung Disease Clinical Trial
Official title:
Validation of VoluSense Pediatrics, a New Method of Infant Spirometry Based on Electromagnetic Inductance Plethysmography
This is a cross-sectional observational study, aiming to validate the accuracy of tidal breathing measurements in infants made by VoluSense Pediatrics, a lung function method based on electromagnetic inductance plethysmography, compared to an ultrasonic flowmeter. VoluSense Pediatrics consists of a flexible vest placed around the torso of the baby, and changes in tidal volume and flow is measured. The study will enable a better understanding of the usefulness of this equipment. The equipment is made by VoluSense Norway AS, and is owned by Haukeland University Hospital.
All infants will be assessed at the pediatric department at Haukeland University Hospital,
and all data obtained by the same two investigators (Bentsen and Olsen). The infants will be
dressed in the appropriate-sized vest selected according to the length from the armpit to
the hip of the child. Care will be taken to ensure that the vest fits snugly around the
torso and that the width of the copper wire zig-zag coveres the entire thorax and abdomen
including the pubic region. The vest will be applied directly to the skin; neither body nor
diaper will be worn underneath. The infants will then be fed before they will be placed
supine in a cot and encouraged to sleep. No sedation will be used. Once the infant has
fallen asleep, data will be collected with VSP for 2-3 minutes before the Exhalyzer D®
neonatal facemask connected in series with the ultrasonic flow sensor will be placed gently,
but firmly over the infant's mouth and nose, ensuring a good seal. Once the facemask is in
place, a marker will be inserted in the VSP recording. The Exhalyzer D® measurement will be
started about thirty seconds after the facemask has been put on, to allow adaptation to the
facemask. Simultaneous recording using both devices will then be done for about 1 minute
before the mask will be removed. New markers will be inserted in the VSP recording as the
Exhalyzer D® measurement is started and stopped facilitating analysis of the same breathing
cycles.
Data will be analysed and graphs will be created with SPSS version 22 (IBM SPSS Statistics,
New York, US) and MedCalc version 13.1 (MedCalc Software, Mariakerke, Belgium). Bland-Altman
plots will be used to visualize agreement between the two measurement techniques. For each
pair of measurements, the pairwise mean of the breathing parameters will be plotted on the
x-axis, and the pairwise difference expressed as a percentage of their mean value on the
y-axis. The mean difference and the 95% limits of agreement and their confidence intervals
will be represented by horizontal lines in the graphs.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02253667 -
Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients
|
N/A | |
Completed |
NCT02217423 -
Abdominal Circumference and Cardiorespiratory Repercussions in Patients Submitted to Physical Therapy
|
N/A | |
Completed |
NCT01679301 -
Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator
|
N/A | |
Completed |
NCT02345135 -
Susceptibility to Infections in Ataxia Telangiectasia
|
N/A | |
Terminated |
NCT00966823 -
Fetal Tracheal Balloon Study in Diaphragmatic Hernia
|
Phase 2 | |
Completed |
NCT00139152 -
Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair
|
Phase 4 | |
Completed |
NCT00052052 -
An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Completed |
NCT00013949 -
Cardiovascular Vulnerability to Particulate Exposure
|
N/A | |
Recruiting |
NCT02963467 -
Effect of Smoking on Ventilation-Perfusion Ratio
|
N/A | |
Recruiting |
NCT02965300 -
The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis
|
N/A | |
Enrolling by invitation |
NCT02946658 -
Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT02913365 -
Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
|
N/A | |
Completed |
NCT01952002 -
Clinical Safety for the Inspiratory Muscle Training
|
N/A | |
Completed |
NCT01735526 -
Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Hematopoietic Stem-cell Transplantation
|
N/A | |
Recruiting |
NCT01450644 -
Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease
|
Phase 2 | |
Completed |
NCT01153321 -
Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Completed |
NCT01215279 -
AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)
|
Phase 2 | |
Completed |
NCT00837681 -
Pulmonary Complications of Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT02055222 -
Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
|
||
Completed |
NCT01222442 -
To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart
|
Phase 1 |